Israel Englander’s Acadia Pharmaceuticals ACAD Stock Holding History

Israel Englander’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-130,900	Closed	-$2.73M	–	6011
2023 Q3	$2.73M	Buy	+130,900	New	+$3.56M	﹤0.01%	3271
2018 Q3	–	Sell	-100,000	Closed	-$1.53M	–	3847
2018 Q2	$1.53M	Buy	+100,000	New	+$1.78M	﹤0.01%	2582
2017 Q1	–	Sell	-25,000	Closed	-$721K	–	3442
2016 Q4	$721K	Sell	25,000 -25,000	-50%	-$661K	﹤0.01%	2435
2016 Q3	$1.59M	Buy	+50,000	New	+$1.7M	﹤0.01%	2051
2016 Q2	–	Sell	-225,000	Closed	-$6.29M	–	3130
2016 Q1	$6.29M	Buy	+225,000	New	+$4.91M	0.02%	1117
2013 Q4	–	Sell	-14,600	Closed	-$401K	–	3411
2013 Q3	$401K	Sell	14,600 -105,700	-88%	-$2.21M	﹤0.01%	2692
2013 Q2	$2.18M	Buy	+120,300	New	+$1.66M	0.01%	1537

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's ACAD Position: Q2 2026 in Review

Israel Englander reduced its Acadia Pharmaceuticals (ACAD) stake by 16% in Q2 2026, selling an estimated $2.54M and leaving 589,924 shares worth $14.9M. The position accounts for 0.01% of the portfolio, ranked #1898.

Israel Englander first reported a position in ACAD in Q2 2013 and has held it in 51 quarters since. The position peaked at $55.5M in Q4 2016. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Israel Englander held 589,924 shares of Acadia Pharmaceuticals worth $14.9M as of Q2 2026.
Israel Englander sold 115,537 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.54M.
Acadia Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1898 holding.
Israel Englander first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
Israel Englander's Acadia Pharmaceuticals position peaked at $55.5M in Q4 2016.
350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.